Monopar Therapeutics (MNPR) announced the first patient ever dosed with MNPR-101-Lu. This novel therapeutic radiopharmaceutical combines MNPR-101, Monopar’s antibody that selectively targets the urokinase plasminogen activator receptor, with the therapeutic radioisotope lutetium-177. uPAR is involved in tumor growth and metastasis, and is found in some of the most aggressive, deadly cancers, including pancreatic, ovarian, triple negative breast, and colorectal cancers.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Monopar Therapeutics price target raised to $37 from $9 at JonesResearch
- Monopar Therapeutics price target raised to $22 from $6 at H.C. Wainwright
- Monopar Therapeutics reports Q3 EPS (37c), consensus (48c)
- Monopar Therapeutics Closes $19.2 Million Stock Offering
- Monopar Therapeutics 1.16M share Spot Secondary priced at $16.25